1
|
Thiem K, Hoeke G, van den Berg S, Hijmans A, Jacobs CWM, Zhou E, Mol IM, Mouktaroudi M, Bussink J, Kanneganti TD, Lutgens E, Stienstra R, Tack CJ, Netea MG, Rensen PCN, Berbée JFP, van Diepen JA. Deletion of hematopoietic Dectin-2 or CARD9 does not protect against atherosclerotic plaque formation in hyperlipidemic mice. Sci Rep 2019; 9:4337. [PMID: 30867470 PMCID: PMC6416398 DOI: 10.1038/s41598-019-40663-x] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2018] [Accepted: 02/21/2019] [Indexed: 01/12/2023] Open
Abstract
Inflammatory reactions activated by pattern recognition receptors (PRRs) on the membrane of innate immune cells play an important role in atherosclerosis. Whether the PRRs of the C-type lectin receptor (CLR) family including Dectin-2 may be involved in the pathogenesis of atherosclerosis remains largely unknown. Recently, the CLR-adaptor molecule caspase recruitment domain family member 9 (CARD9) has been suggested to play a role in cardiovascular pathologies as it provides the link between CLR activation and transcription of inflammatory cytokines as well as immune cell recruitment. We therefore evaluated whether hematopoietic deletion of Dectin-2 or CARD9 reduces inflammation and atherosclerosis development. Low-density lipoprotein receptor (Ldlr)-knockout mice were transplanted with bone marrow from wild-type, Dectin-2- or Card9-knockout mice and fed a Western-type diet containing 0.1% (w/w) cholesterol. After 10 weeks, lipid and inflammatory parameters were measured and atherosclerosis development was determined. Deletion of hematopoietic Dectin-2 or CARD9 did not influence plasma triglyceride and cholesterol levels. Deletion of hematopoietic Dectin-2 did not affect atherosclerotic lesion area, immune cell composition, ex vivo cytokine secretion by peritoneal cells or bone marrow derived macrophages. Unexpectedly, deletion of hematopoietic CARD9 increased atherosclerotic lesion formation and lesion severity. Deletion of hematopoietic CARD9 did also not influence circulating immune cell composition and peripheral cytokine secretion. Besides a tendency to a reduced macrophage content within these lesions, plasma MCP-1 levels decreased upon WTD feeding. Deletion of hematopoietic Dectin-2 did not influence atherosclerosis development in hyperlipidemic mice. The absence of CARD9 unexpectedly increased atherosclerotic lesion size and severity, suggesting that the presence of CARD9 may protect against initiation of atherosclerosis development.
Collapse
Affiliation(s)
- Kathrin Thiem
- Department of Internal Medicine and Radboud Institute for Molecular Life Sciences, Radboud university medical center, Nijmegen, The Netherlands.
| | - Geerte Hoeke
- Department of Medicine, Div. of Endocrinology, Leiden University Medical Center, Leiden, The Netherlands.,Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The Netherlands
| | - Susan van den Berg
- Department of Medical Biochemistry, Div. of Experimental Vascular Biology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
| | - Anneke Hijmans
- Department of Internal Medicine and Radboud Institute for Molecular Life Sciences, Radboud university medical center, Nijmegen, The Netherlands
| | - Cor W M Jacobs
- Department of Internal Medicine and Radboud Institute for Molecular Life Sciences, Radboud university medical center, Nijmegen, The Netherlands
| | - Enchen Zhou
- Department of Medicine, Div. of Endocrinology, Leiden University Medical Center, Leiden, The Netherlands.,Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The Netherlands
| | - Isabel M Mol
- Department of Medicine, Div. of Endocrinology, Leiden University Medical Center, Leiden, The Netherlands.,Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The Netherlands
| | - Maria Mouktaroudi
- Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School, Athens, Greece
| | - Johan Bussink
- Dept. of Radiation Oncology, Radboud University Medical Center, Nijmegen, The Netherlands
| | | | - Esther Lutgens
- Department of Medical Biochemistry, Div. of Experimental Vascular Biology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.,Institute for Cardiovascular Prevention, Ludwig Maximilians University of Munich, Munich, Germany
| | - Rinke Stienstra
- Department of Internal Medicine and Radboud Institute for Molecular Life Sciences, Radboud university medical center, Nijmegen, The Netherlands.,Div. of Human Nutrition, Wageningen University, Wageningen, The Netherlands
| | - Cees J Tack
- Department of Internal Medicine and Radboud Institute for Molecular Life Sciences, Radboud university medical center, Nijmegen, The Netherlands
| | - Mihai G Netea
- Department of Internal Medicine and Radboud Institute for Molecular Life Sciences, Radboud university medical center, Nijmegen, The Netherlands.,Department for Genomics & Immunoregulation, Life and Medical Sciences Institute (LIMES), University of Bonn, Bonn, Germany
| | - Patrick C N Rensen
- Department of Medicine, Div. of Endocrinology, Leiden University Medical Center, Leiden, The Netherlands.,Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The Netherlands
| | - Jimmy F P Berbée
- Department of Medicine, Div. of Endocrinology, Leiden University Medical Center, Leiden, The Netherlands.,Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The Netherlands
| | - Janna A van Diepen
- Department of Internal Medicine and Radboud Institute for Molecular Life Sciences, Radboud university medical center, Nijmegen, The Netherlands
| |
Collapse
|
2
|
Shami A, Aarts S, Bürger C, Kusters P, van den Berg S, Seijkens T, Kooij G, Weber C, Gerdes N, de Winther M, Lutgens E. Abstract 441: Macrophage CD40 in Atherosclerosis, Obesity and Multiple Sclerosis. Arterioscler Thromb Vasc Biol 2017. [DOI: 10.1161/atvb.37.suppl_1.441] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Introduction:
The co-stimulatory dyad CD40-CD40L plays a central role in fine-tuning immune reactions in atherosclerosis, obesity-induced inflammation and multiple sclerosis (MS). Inhibition of CD40 in atherosclerosis and experimental autoimmune encephalomyelitis (EAE) ameliorates disease outcome, whereas CD40-deficiency in a diet induced obesity (DIO) model worsens insulin resistance and induces excessive adipose tissue inflammation. Although inhibition of CD40 has powerful effects, we do not know which CD40 expressing cell-type is responsible for the amelioration/aggravation of disease. As myeloid CD40 is known to play a role in leukocyte trafficking, which is important in atherosclerosis, obesity and neuro-inflammation, we hypothesize that myeloid CD40 is important in these disease modalities.
Methods:
To investigate the role of myeloid CD40 in atherosclerosis, obesity and EAE we have generated macrophage specific LysM-CD40flfl
-
(ApoE-/-), and dendritic cell/adipose tissue macrophage specific CD11C-CD40flfl). Atherosclerosis was induced by aging the LysM-CD40flfl
-
ApoE-/- mice until 30 weeks. EAE was induced in LysM-CD40flfl mice by subjecting them to myelin oligodendrocyte glycoprotein peptide (MOG35-55), and LysM-CD40flfl and CD11c-CD40flfl mice were subjected to a 60% high fat diet for 18 wks.
Results:
LysM-CD40flfl
-
ApoE-/- mice showed a significant reduction in atherosclerotic plaque area, with a reduced macrophage accumulation. Loss of macrophage CD40 in EAE results in a significant decrease in the neurological symptoms of EAE, and a majority of the LysM-CD40flfl mice were fully protected against EAE. LysM-CD40flfl mice subjected to DIO showed an increase in macrophage accumulation in the visceral adipose tissue, but did not affect adipose tissue mass, insulin tolerance, or plasma triglyceride concentrations. The CD11CcreCD40flfl mice exhibited a decrease in visceral adipose tissue weight, an increased lipid content in the liver and slightly decreases leukocyte numbers and pro-inflammatory gene expression in the adipose tissue.
Conclusions:
Macrophage CD40 is an important driver of atherosclerosis and EAE. Macrophage CD40 is protective in obesity-induced inflammation, but is probably not the key player.
Collapse
Affiliation(s)
- Annelie Shami
- Academic Med Cntr, Univ of Amsterdam, Amsterdam, Netherlands
| | - Suzanne Aarts
- Academic Med Cntr, Univ of Amsterdam, Amsterdam, Netherlands
| | - Christina Bürger
- Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians Univ Munich, Munich, Germany
| | - Pascal Kusters
- Academic Med Cntr, Univ of Amsterdam, Amsterdam, Netherlands
| | | | - Tom Seijkens
- Academic Med Cntr, Univ of Amsterdam, Amsterdam, Netherlands
| | - Gijs Kooij
- Dept of Molecular Cell Biology and Immunology, Neuroscience Campus Amsterdam, VU Univ Med Cntr, Amsterdam, Netherlands
| | - Christian Weber
- Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians Univ Munich, Munich, Germany
| | - Norbert Gerdes
- Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians Univ Munich, Munich, Germany
| | | | - Esther Lutgens
- Academic Med Cntr, Univ of Amsterdam, Amsterdam, Netherlands
| |
Collapse
|
4
|
Chatzigeorgiou A, Seijkens T, Zarzycka B, Engel D, Poggi M, van den Berg S, van den Berg S, Soehnlein O, Winkels H, Beckers L, Lievens D, Driessen A, Kusters P, Biessen E, Garcia-Martin R, Klotzsche-von Ameln A, Gijbels M, Noelle R, Boon L, Hackeng T, Schulte KM, Xu A, Vriend G, Nabuurs S, Chung KJ, Willems van Dijk K, Rensen PCN, Gerdes N, de Winther M, Block NL, Schally AV, Weber C, Bornstein SR, Nicolaes G, Chavakis T, Lutgens E. Blocking CD40-TRAF6 signaling is a therapeutic target in obesity-associated insulin resistance. Proc Natl Acad Sci U S A 2014; 111:2686-91. [PMID: 24492375 PMCID: PMC3932883 DOI: 10.1073/pnas.1400419111] [Citation(s) in RCA: 100] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
The immune system plays an instrumental role in obesity and insulin resistance. Here, we unravel the role of the costimulatory molecule CD40 and its signaling intermediates, TNF receptor-associated factors (TRAFs), in diet-induced obesity (DIO). Although not exhibiting increased weight gain, male CD40(-/-) mice in DIO displayed worsened insulin resistance, compared with wild-type mice. This worsening was associated with excessive inflammation of adipose tissue (AT), characterized by increased accumulation of CD8(+) T cells and M1 macrophages, and enhanced hepatosteatosis. Mice with deficient CD40-TRAF2/3/5 signaling in MHCII(+) cells exhibited a similar phenotype in DIO as CD40(-/-) mice. In contrast, mice with deficient CD40-TRAF6 signaling in MHCII(+) cells displayed no insulin resistance and showed a reduction in both AT inflammation and hepatosteatosis in DIO. To prove the therapeutic potential of inhibition of CD40-TRAF6 in obesity, DIO mice were treated with a small-molecule inhibitor that we designed to specifically block CD40-TRAF6 interactions; this compound improved insulin sensitivity, reduced AT inflammation, and decreased hepatosteatosis. Our study reveals that the CD40-TRAF2/3/5 signaling pathway in MHCII(+) cells protects against AT inflammation and metabolic complications associated with obesity whereas CD40-TRAF6 interactions in MHCII(+) cells aggravate these complications. Inhibition of CD40-TRAF6 signaling by our compound may provide a therapeutic option in obesity-associated insulin resistance.
Collapse
Affiliation(s)
- Antonios Chatzigeorgiou
- Department of Clinical Pathobiochemistry, Technische Universität Dresden, 01307 Dresden, Germany
- Department of Medicine, Technische Universität Dresden, 01307 Dresden, Germany
- Paul-Langerhans Institute Dresden, German Center for Diabetes Research, 01307 Dresden, Germany
| | - Tom Seijkens
- Department of Medical Biochemistry, Subdivision of Experimental Vascular Biology, Academic Medical Center, University of Amsterdam, 1105 AZ, Amsterdam, The Netherlands
| | - Barbara Zarzycka
- Department of Biochemistry, University of Maastricht, 6229 ER, Maastricht, The Netherlands
| | - David Engel
- Department of Pathology, University of Maastricht, 6229 ER, Maastricht, The Netherlands
| | - Marjorie Poggi
- Department of Pathology, University of Maastricht, 6229 ER, Maastricht, The Netherlands
- Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche 1062, and Faculté de Médecine, Aix-Marseille Université, F-13385 Marseille, France
| | - Susan van den Berg
- Department of Medical Biochemistry, Subdivision of Experimental Vascular Biology, Academic Medical Center, University of Amsterdam, 1105 AZ, Amsterdam, The Netherlands
| | - Sjoerd van den Berg
- Department of Human Genetics, Leiden University Medical Center, 2333 ZA, Leiden, The Netherlands
| | - Oliver Soehnlein
- Department of Pathology, Academic Medical Center, University of Amsterdam, 1105 AZ, Amsterdam, The Netherlands
- Institute for Cardiovascular Prevention, Ludwig Maximilians University, 80336 Munich, Germany
| | - Holger Winkels
- Department of Medical Biochemistry, Subdivision of Experimental Vascular Biology, Academic Medical Center, University of Amsterdam, 1105 AZ, Amsterdam, The Netherlands
- Institute for Cardiovascular Prevention, Ludwig Maximilians University, 80336 Munich, Germany
| | - Linda Beckers
- Department of Medical Biochemistry, Subdivision of Experimental Vascular Biology, Academic Medical Center, University of Amsterdam, 1105 AZ, Amsterdam, The Netherlands
| | - Dirk Lievens
- Department of Medical Biochemistry, Subdivision of Experimental Vascular Biology, Academic Medical Center, University of Amsterdam, 1105 AZ, Amsterdam, The Netherlands
- Institute for Cardiovascular Prevention, Ludwig Maximilians University, 80336 Munich, Germany
| | - Ann Driessen
- Department of Pathology, University of Antwerp, 2650 Antwerp, Belgium
| | - Pascal Kusters
- Department of Medical Biochemistry, Subdivision of Experimental Vascular Biology, Academic Medical Center, University of Amsterdam, 1105 AZ, Amsterdam, The Netherlands
| | - Erik Biessen
- Department of Pathology, University of Maastricht, 6229 ER, Maastricht, The Netherlands
| | - Ruben Garcia-Martin
- Department of Clinical Pathobiochemistry, Technische Universität Dresden, 01307 Dresden, Germany
| | - Anne Klotzsche-von Ameln
- Department of Clinical Pathobiochemistry, Technische Universität Dresden, 01307 Dresden, Germany
| | - Marion Gijbels
- Department of Medical Biochemistry, Subdivision of Experimental Vascular Biology, Academic Medical Center, University of Amsterdam, 1105 AZ, Amsterdam, The Netherlands
- Department of Pathology, University of Maastricht, 6229 ER, Maastricht, The Netherlands
- Cardiovascular Research Institute Maastricht, Maastricht University, 6229 ER, Maastricht, The Netherlands
| | - Randolph Noelle
- Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Lebanon, NH 03766
- Medical Research Council Centre of Transplantation, Guy’s Hospital, King’s College London, London SE1 9RT, United Kingdom
| | - Louis Boon
- Bioceros BV, 3584 CM, Utrecht, The Netherlands
| | - Tilman Hackeng
- Department of Biochemistry, University of Maastricht, 6229 ER, Maastricht, The Netherlands
| | - Klaus-Martin Schulte
- Department of Endocrine Surgery, King's College Hospital, Denmark Hill, London SE5 9RS, United Kingdom
| | - Aimin Xu
- Department of Medicine, University of Hong Kong, Hong Kong, China
| | - Gert Vriend
- Centre for Molecular and Biomolecular Informatics, Radboud University Medical Center, 6295 EN, Nijmegen, The Netherlands
| | - Sander Nabuurs
- Centre for Molecular and Biomolecular Informatics, Radboud University Medical Center, 6295 EN, Nijmegen, The Netherlands
- Lead Pharma Medicine, 6525 EN, Nijmegen, The Netherlands
| | - Kyoung-Jin Chung
- Department of Clinical Pathobiochemistry, Technische Universität Dresden, 01307 Dresden, Germany
| | - Ko Willems van Dijk
- Department of Human Genetics, Leiden University Medical Center, 2333 ZA, Leiden, The Netherlands
- Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, 2333 ZA, Leiden, The Netherlands
| | - Patrick C. N. Rensen
- Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, 2333 ZA, Leiden, The Netherlands
- Department of Endocrinology, Leiden University Medical Center, 2333 ZA, Leiden, The Netherlands
| | - Norbert Gerdes
- Department of Medical Biochemistry, Subdivision of Experimental Vascular Biology, Academic Medical Center, University of Amsterdam, 1105 AZ, Amsterdam, The Netherlands
- Institute for Cardiovascular Prevention, Ludwig Maximilians University, 80336 Munich, Germany
| | - Menno de Winther
- Department of Medical Biochemistry, Subdivision of Experimental Vascular Biology, Academic Medical Center, University of Amsterdam, 1105 AZ, Amsterdam, The Netherlands
| | - Norman L. Block
- Divisions of Endocrinology and Hematology–Oncology, Departments of Pathology and Medicine, University of Miami Miller School of Medicine, Miami, FL 33136
- Veterans Affairs Medical Center, Miami, FL 33125
| | - Andrew V. Schally
- Divisions of Endocrinology and Hematology–Oncology, Departments of Pathology and Medicine, University of Miami Miller School of Medicine, Miami, FL 33136
- Veterans Affairs Medical Center, Miami, FL 33125
| | - Christian Weber
- Department of Biochemistry, University of Maastricht, 6229 ER, Maastricht, The Netherlands
- Institute for Cardiovascular Prevention, Ludwig Maximilians University, 80336 Munich, Germany
- German Centre for Cardiovascular Research, Munich, 80336, Germany
| | - Stefan R. Bornstein
- Department of Medicine, Technische Universität Dresden, 01307 Dresden, Germany
- Diabetes and Nutritional Sciences Division, King's College London, Denmark Hill, London SE5 9NU, United Kingdom; and
| | - Gerry Nicolaes
- Department of Biochemistry, University of Maastricht, 6229 ER, Maastricht, The Netherlands
| | - Triantafyllos Chavakis
- Department of Clinical Pathobiochemistry, Technische Universität Dresden, 01307 Dresden, Germany
- Department of Medicine, Technische Universität Dresden, 01307 Dresden, Germany
- Paul-Langerhans Institute Dresden, German Center for Diabetes Research, 01307 Dresden, Germany
- Institute for Clinical Chemistry and Laboratory Medicine, Technische Universität Dresden, 01307 Dresden, Germany
| | - Esther Lutgens
- Department of Medical Biochemistry, Subdivision of Experimental Vascular Biology, Academic Medical Center, University of Amsterdam, 1105 AZ, Amsterdam, The Netherlands
- Institute for Cardiovascular Prevention, Ludwig Maximilians University, 80336 Munich, Germany
| |
Collapse
|